Aug 21, 2024 | Chemical Injury, Defective Product, Formaldehyde Exposure, Personal Injury, Product Liability, Work Injury
Formaldehyde is a chemical compound commonly used in a variety of consumer products and industrial applications. Its inclusion in everyday items such as cosmetics, furniture, building materials, and even personal care products is due to its preservative and...
Aug 20, 2024 | Defective Drugs, Defective Medical Device, Defective Product, Product Liability, Tepezza Injuries
Tepezza (teprotumumab-trbw) is a breakthrough medication used to treat thyroid eye disease (TED), a rare condition that causes inflammation and bulging of the eyes. Tepezza was approved by the U.S. Food and Drug Administration (FDA) in January 2020 and has been...
Aug 14, 2024 | Defective Drugs, Defective Product, Medical News, Ozempic Injury, Ozempic Lawsuit, Ozempic Lawsuits, Product Liability
Ozempic, a medication primarily used to manage type 2 diabetes, has garnered significant attention due to its ability to help control blood sugar levels and promote weight loss. However, like many pharmaceuticals, Ozempic comes with potential side effects. Among...
Aug 8, 2024 | Defective Medical Device, Defective Product, Medical News, Product Liability
Bard PowerPort devices, used in medical treatments requiring frequent injections or infusions, have been the subject of increasing scrutiny due to reports of severe injuries and complications. As a result, many patients and their families are considering legal action...
Aug 6, 2024 | Defective Drugs, Defective Product, Medical News, Product Liability
Tepezza (teprotumumab) has emerged as a groundbreaking treatment for Thyroid Eye Disease (TED), a condition that can cause bulging eyes, double vision, and other serious issues. While Tepezza has offered hope to many patients, it has also raised concerns due to...
Aug 2, 2024 | Defective Drugs, Defective Product, Medical News, Ozempic Injury, Ozempic Lawsuit, Personal Injury
Ozempic (semaglutide) is a prescription medication primarily used to improve blood sugar control in adults with type 2 diabetes. Approved by the U.S. Food and Drug Administration (FDA) in 2017, Ozempic belongs to a class of drugs known as GLP-1 receptor agonists....
